Welcome to China Oncology,
China Oncology ›› 2024, Vol. 34 ›› Issue (11): 1061-1066.doi: 10.19401/j.cnki.1007-3639.2024.11.009
LI Jun1(
), LU Tingwei2, FANG Xuqian2()
Received:2024-05-07
Revised:2024-09-20
Online:2024-11-30
Published:2024-12-11
Contact:
FANG Xuqian
Share article
CLC Number:
LI Jun, LU Tingwei, FANG Xuqian. Impact of MSI-H/dMMR on clinicopathological characteristics and prognosis of patients with BRAF V600E-mutated resectable colorectal cancer[J]. China Oncology, 2024, 34(11): 1061-1066.
Fig. 1
Molecular subtyping of CRC patients through BRAF, MSI and MMR detection"
Tab. 1
Comparison of clinical and pathological characteristics between MSS type and MSI-H/dMMR type BRAF mutated colorectal cancer patients"
| Characteristic | BRAF＋ (n=54) | BRAF＋, MSS (n=38) | BRAF＋, MSI-H/dMMR (n=16) | χ2 value | P value |
|---|---|---|---|---|---|
| Gender n | 4.15 | 0.042 | |||
| Male | 25 | 21 | 4 | ||
| Female | 29 | 17 | 12 | ||
| Age/year | 65.59±12.92 | 62.39±13.02 | 73.19±9.19 | 0.004# | |
| Location n | 4.88 | 0.027 | |||
| Left half | 26 | 22 | 4 | ||
| Right half | 28 | 16 | 12 | ||
| dMMR n (%) | |||||
| MLH1- | 16 (29.7) | 0 (0.0) | 16 (100.0) | ||
| PMS2- | 16 (29.7) | 0 (0.0) | 16 (100.0) | ||
| MSH2- | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| MSH6- | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Colorectal cancer radical surgery n (%) | 51 (94.4) | 35 (92.1) | 16 (100.0) | 0.546# | |
| T stage n | 1.50 | 0.682 | |||
| T1 | 4 | 2 | 2 | ||
| T2 | 1 | 1 | 0 | ||
| T3 | 36 | 25 | 11 | ||
| T4 | 13 | 10 | 3 | ||
| N stage n | 16.34 | 0.000 | |||
| N0 | 25 | 11 | 14 | ||
| N1 | 13 | 11 | 2 | ||
| N2 | 16 | 16 | 0 | ||
| M stage n | 5.816 | 0.016 | |||
| M0 | 43 | 27 | 16 | ||
| M1 | 11 | 11 | 0 | ||
| Clinical stage n | 21.39 | <0.0001 | |||
| Ⅰ | 4 | 2 | 2 | ||
| Ⅱ | 18 | 6 | 12 | ||
| Ⅲ | 20 | 18 | 2 | ||
| Ⅳ | 12 | 12 | 0 |
Fig. 2
Survival comparison between MSS type and MSI-H type BRAF-mutated colorectal cancer The prognosis of MSI-H tumors is markedly superior to that of MSS tumors."
| [1] |
VILAR E, GRUBER S B. Microsatellite instability in colorectal cancer-the stable evidence[J]. Nat Rev Clin Oncol, 2010, 7(3): 153-162.
doi: 10.1038/nrclinonc.2009.237 pmid: 20142816 |
| [2] | 中国临床肿瘤学会结直肠癌专家委员会, 中国抗癌协会大肠癌专业委员会遗传学组, 中国医师协会结直肠肿瘤专业委员会遗传专委会. 结直肠癌及其他相关实体瘤微卫星不稳定性检测中国专家共识[J]. 中华肿瘤杂志, 2019. 41(10): 734-741. |
| The Colorectal Cancer Expert Committee of Chinese Society of Clinical Oncology, the Genetics Group of the Colorectal Cancer Professional Committee of China Anti-Cancer Association, and the Genetics Committee of the Colorectal Cancer Professional Committee of Chinese Medical Doctor Association. Consensus on the detection of microsatellite instability in colorectal cancer and other related solid tumors in China[J]. Chin J Oncol, 2019. 41(10): 734-741. | |
| [3] |
黎相照, 刘焕娇, 梁敏仪, 等. 微卫星不稳定性类型及临床病理特征:基于1394例结直肠癌患者的标本检测[J]. 南方医科大学学报, 2020, 40(11): 1645-1650.
doi: 10.12122/j.issn.1673-4254.2020.11.17 |
| LI X Z, LIU H J, LIANG M Y, et al. Clinicopathological features and types of microsatellite instability in 1394 patients with colorectal cancer[J]. J South Med Univ, 2020, 40(11): 1645-1650. | |
| [4] |
DIENSTMANN R, VERMEULEN L, GUINNEY J, et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer[J]. Nat Rev Cancer, 2017, 17(2): 79-92.
doi: 10.1038/nrc.2016.126 pmid: 28050011 |
| [5] |
GROTHEY A, FAKIH M, TABERNERO J. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines[J]. Ann Oncol, 2021, 32(8): 959-967.
doi: 10.1016/j.annonc.2021.03.206 pmid: 33836264 |
| [6] | Chinese Society of Clinical Oncology Diagnosis and Treatment Guidelines for Colorectal Cancer Working Group. Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)[J]. Chin J Cancer Res, 2019, 31(1): 117-134. |
| [7] |
OLIVEIRA A F, BRETES L, FURTADO I. Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer[J]. Front Oncol, 2019, 9: 396.
doi: 10.3389/fonc.2019.00396 pmid: 31139574 |
| [8] | SARIDAKI Z, SOUGLAKOS J, GEORGOULIAS V. Prognostic and predictive significance of MSI in stages Ⅱ/Ⅲ colon cancer[J]. World J Gastroenterol, 2014, 20(22): 6809-6814. |
| [9] | HESTETUN K E, ROSENLUND N B, STANISAVLJEVIĆ L, et al. Stage-dependent prognostic shift in mismatch repair-deficient tumors: assessing patient outcomes in stage Ⅱ and Ⅲ colon cancer[J]. Front Oncol, 2022, 12: 853545. |
| [10] | FUJIYOSHI K, YAMAMOTO G, TAKENOYA T, et al. Metastatic pattern of stage Ⅳ colorectal cancer with high-frequency microsatellite instability as a prognostic factor[J]. Anticancer Res, 2017, 37(1): 239-247. |
| [11] | LOUPAKIS F, CREMOLINI C, MASI G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer[J]. N Engl JMed, 2014, 371(17): 1609-1618. |
| [12] | MAURI G, BONAZZINA E, AMATU A, et al. The evolutionary landscape of treatment for BRAF V600E mutant metastatic colorectal cancer[J]. Cancers, 2021, 13(1): 137. |
| [13] |
GUINNEY J, DIENSTMANN R, WANG X, et al. The consensus molecular subtypes of colorectal cancer[J]. Nat Med, 2015, 21(11): 1350-1356.
doi: 10.1038/nm.3967 pmid: 26457759 |
| [14] | JOANITO I, WIRAPATI P, ZHAO N, et al. Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer[J]. Nat Genet, 2022, 54(7): 963-975. |
| [15] | 郑民华, 张森, 马君俊. 结直肠癌的分子分型与精准治疗策略:从经验到精确[J]. 中华消化外科杂志, 2023, 22(10): 1155-1159. |
| ZHENG M H, ZHANG S, MA J J. Molecular typing and precise treatment strategies for colorectal cancer: from experience to precision[J]. Chin j Dig Surg, 2023, 22(10): 1155-1159. | |
| [16] |
LIU Q, LUO D K, CAI S J, et al. P-TNM staging system for colon cancer: combination of P-stage and AJCC TNM staging system for improving prognostic prediction and clinical management[J]. Cancer Manag Res, 2018, 10: 2303-2314.
doi: 10.2147/CMAR.S165188 pmid: 30104899 |
| [17] |
HATCH S B, LIGHTFOOT H M JR, GARWACKI C P, et al. Microsatellite instability testing in colorectal carcinoma: choice of markers affects sensitivity of detection of mismatch repair-deficient tumors[J]. Clin Cancer Res, 2005, 11(6): 2180-2187.
doi: 10.1158/1078-0432.CCR-04-0234 pmid: 15788665 |
| [18] |
COLLE R, LONARDI S, CACHANADO M, et al. BRAF V600E/RAS mutations and Lynch syndrome in patients with MSI-H/dMMR metastatic colorectal cancer treated with immune checkpoint inhibitors[J]. Oncologist, 2023, 28(9): 771-779.
doi: 10.1093/oncolo/oyad082 pmid: 37023721 |
| [19] |
VENDERBOSCH S, NAGTEGAAL I D, MAUGHAN T S, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies[J]. Clin Cancer Res, 2014, 20(20): 5322-5330.
doi: 10.1158/1078-0432.CCR-14-0332 pmid: 25139339 |
| [20] | AASEBØ K Ø, DRAGOMIR A, SUNDSTRÖM M, et al. Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: a population-based cohort of metastatic colorectal cancer patients[J]. Cancer Med, 2019, 8(7): 3623-3635. |
| [21] | 杨利华, 杨树东. RAS、BRAF基因突变及HER2基因扩增与结直肠癌患者临床病理特征及预后的关系[J]. 中华普通外科杂志, 2022, 37(11): 845-849. |
| YANG L H, YANG S D. Relationship between RAS, BRAF gene mutations and HER2 gene amplification and clinicopathology and prognosis of colorectal cancer[J]. Chin J Gen Surg, 2022, 37(11): 845-849. | |
| [22] | YAEGER R, CERCEK A, CHOU J F, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer[J]. Cancer, 2014, 120(15): 2316-2324. |
| [23] |
TAIEB J, SVRCEK M, COHEN R, et al. Deficient mismatch repair/microsatellite unstable colorectal cancer: diagnosis, prognosis and treatment[J]. Eur J Cancer, 2022, 175: 136-157.
doi: 10.1016/j.ejca.2022.07.020 pmid: 36115290 |
| [24] | NAKAYAMA I, HIROTA T, SHINOZAKI E. BRAF mutation in colorectal cancers: from prognostic marker to targetable mutation[J]. Cancers, 2020, 12(11): 3236. |
| [25] | KARKI S, SUN W J, MADAN R, et al. Microsatellite instability with BRAF V600E associated with delayed presentation but poor survival in stage Ⅲ colorectal cancer[J]. Fortune J Health Sci, 2023, 6(2): 167-173. |
| [26] |
DIAZ L A JR, SHIU K K, KIM T W, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study[J]. Lancet Oncol, 2022, 23(5): 659-670.
doi: 10.1016/S1470-2045(22)00197-8 pmid: 35427471 |
| [27] | DING Y W, WENG S S, LI X Y, et al. General treatment for metastatic colorectal cancer: from KEYNOTE 177 study[J]. Transl Oncol, 2021, 14(8): 101122. |
| [28] | JOHNSON B, KOPETZ S. Applying precision to the management of BRAF-mutant metastatic colorectal cancer[J]. Target Oncol, 2020, 15(5): 567-577. |
| [1] | HUANG Haozhe, CHEN Hong, ZHENG Dezhong, CHEN Chao, WANG Ying, XU Lichao, WANG Yaohui, HE Xinhong, YANG Yuanyuan, LI Wentao. A CT-based radiomics nomogram for predicting local tumor progression of colorectal cancer lung metastases treated with radiofrequency ablation [J]. China Oncology, 2024, 34(9): 857-872. |
| [2] | WU Wen, ZHANG Ruoxin, WENG Junyong, MA Yanlei, CAI Guoxiang, LI Xinxiang, YANG Yongzhi. Exploring the prognostic value of positive lymph node ratio in stage Ⅲ colorectal cancer patients and establishing a predictive model [J]. China Oncology, 2024, 34(9): 873-880. |
| [3] | XIAO Feng, XU Tonglin, ZHU Lin, XIAO Jingwen, WU Tianqi, GU Chunyan. Significance of infiltration of M1 tumor-associated macrophages in hepatocellular carcinoma [J]. China Oncology, 2024, 34(8): 726-733. |
| [4] | GE Zuyin, SONG Kun, LIN Yunxiao, ZHONG Yeling, HAO Jingduo. The feasibility study of FCGBP and BIGH3 in circulating tumor cells as potential markers for colorectal cancer [J]. China Oncology, 2024, 34(8): 745-752. |
| [5] | WENG Junyong, YE Zilan, ZHANG Ruoxin, LIU Qi, LI Xinxiang. Exploring the guiding role of the number of adverse pathological features in risk stratification for recurrence of stage Ⅰ-Ⅲ colorectal cancer: a retrospective cohort study of 9 875 cases [J]. China Oncology, 2024, 34(6): 527-536. |
| [6] | ZHANG Ruoxin, YE Zilan, WENG Junyong, LI Xinxiang. Correlation study between advanced age and inferior prognosis in stage Ⅱ colorectal cancer patients [J]. China Oncology, 2024, 34(5): 485-492. |
| [7] | LU Yue, LU Renquan, ZHANG Jie, ZHENG Hui. Application value of combined coagulation function indicators in monitoring hypercoagulable state of patients with colorectal cancer after chemotherapy [J]. China Oncology, 2024, 34(3): 278-285. |
| [8] | WU Zhibai, XU Guiqin, ZHANG Li, YANG Zhaojuan, LIU Yun, JIAO Kun, CHEN Zehong, XU Chen, ZUO You, ZHENG Ningqian, YE Zhiqian, LIU Yongzhong. Mechanism study of KCMF1 promoting proliferation and NF-κB signaling transduction in colorectal cancer cells [J]. China Oncology, 2024, 34(11): 987-997. |
| [9] | ZHANG Shaohua, LI Zhening, WANG Wei, WEI Yifan, HONG Yonggang, HAO Liqiang. Research progress in the related treatment of KRAS mutant colorectal cancer [J]. China Oncology, 2024, 34(10): 979-986. |
| [10] | Colorectal Cancer Special Committee of Shanghai Anti-Cancer Association . Shanghai plan for early screening, diagnosis and treatment of colorectal cancer (2023 edition) [J]. China Oncology, 2024, 34(1): 13-66. |
| [11] | WU Han, XU Lei, WANG Miaomiao, ZHANG Ruizhe, XU Xiaoyang, GUO Ningjie, WU Shuhua. Correlation of LC3 and the recruitment of dendritic cell and the formation of TLS in colorectal cancer and its clinical significance [J]. China Oncology, 2023, 33(9): 818-828. |
| [12] | JIN Yizi, LIN Mingxi, ZHANG Jian. Receptor discordance between primary breast cancer and liver metastases [J]. China Oncology, 2023, 33(9): 834-843. |
| [13] | WU Han, YANG Zhangru, FENG Wen, ZENG Wanqin, GUO Jindong, LI Hongxuan, WANG Changlu, WANG Jiaming, LÜ Changxing, ZHANG Qin, YU Wen, CAI Xuwei, FU Xiaolong. The efficacy and prognosis analysis after stereotactic body radiotherapy for multiple primary early-stage lung cancer [J]. China Oncology, 2023, 33(9): 844-856. |
| [14] | CHEN Jinjuan, WANG Xingran, LI Wenzhi, CHENG Yu, SUN Yihua, TAO Xiang, MA Fenghua, SUN Li, ZHAO Hongbo, LU Xin. Conservative surgery in stage I placental site trophoblastic tumor: a report of 10 cases and literature review [J]. China Oncology, 2023, 33(9): 857-865. |
| [15] | SUN Yang, WANG Lian, ZHAO Meng, ZHANG Xiaofeng, GENG Zhijun, WANG Yueyue, SONG Xue, ZUO Lugen, LI Jing, HU Jianguo. The prognostic value of high expression of FKBP1A in gastric cancer and the regulatory effect of targeted PI3K/AKT on glucose metabolism [J]. China Oncology, 2023, 33(8): 726-739. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd
